MonoSol Rx Appoints John T. Maxwell as Chief Financial Officer

WARREN, N.J., Jan. 24, 2017 -- MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, today announced the appointment of John T. Maxwell as its Chief Financial Officer, effective January 9, 2017. Mr. Maxwell will lead the Company’s financial and administrative operations.

“John has a unique skill-set and a wealth of public and private company experience, qualities that we believe will be crucial as we continue growing MonoSol Rx and advancing our pipeline of PharmFilm-based product candidates. He has a demonstrated track record of financial and operational leadership including improvement of financial results through revenue growth and expense management, M&A and capital markets transactions,” said Keith Kendall, Chief Executive Officer of MonoSol Rx.  “He has a great deal of expertise growing companies at various stages, and I am confident that his contributions will have a significant impact on MonoSol Rx’s future success.”

Mr. Maxwell has more than 30 years of experience in finance, accounting and management at companies in a variety of industries including healthcare, satellite communications and information services. Prior to joining MonoSol Rx, Mr. Maxwell served as Chief Financial Officer of WIL Research Company from 2008 until its sale to Charles River Laboratories in April 2016. WIL is a contract research organization focused on preclinical R&D and clinical trials contract manufacturing for the biopharma, chemical, agrichemical, food and biocides industries. Under Mr. Maxwell’s leadership, WIL’s business grew at an 11% CAGR by increasing market share and market position in the early stage CRO industry. From 2000-2006, he served as SVP-Finance & Administration at PanAmSat (acquired by Intelsat), one of the world’s largest satellite communications providers, where he played a key role in the Company’s capital markets activities including its $900 million IPO,  multiple public debt transactions and the $6 billion sale of the Company. Mr. Maxwell began his career at Ernst & Young where he spent two of his seven years in the National / New York technical accounting office.  Mr. Maxwell is a licensed CPA, and he holds a BBA in accounting from Texas Tech University and an MBA from New York University Stern School of Business.

Mr. Maxwell added, “I am extremely proud to join the world-class leadership team at MonoSol Rx and look forward to leading the Company into its next phase of growth and success. We have reached a number of important milestones recently, including submission of the New Drug Application for Tadalafil PharmFilm®, securing Orphan Drug Designation for Diazepam Buccal Soluble Film (Diazepam BSF) to treat Acute Repetitive Seizures (ARS) and FDA acceptance of our Investigational New Drug application for Riluzole Oral Soluble Film to treat Amyotrophic Lateral Sclerosis. We have multiple catalysts expected in the coming months as well, such as the initiation of a human proof-of-concept study of Epinephrine Sublingual Soluble Film and a pivotal study of Diazepam BSF in ARS. This is truly an exciting time for MonoSol Rx, and I am thrilled with the prospect of helping bring unique therapies to patients in need.”

About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs.   PharmFilm can benefit patients by improving the efficacy, safety, convenience, and compliance of pharmaceutical products. MonoSol Rx's leadership in film drug technology is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com.

Contact

MonoSol Rx
Jessica Patel
[email protected]

The Ruth Group
Lee Roth 
[email protected]
(646) 536-7012